Dual phase helical CT versus portal venous phase CT for the detection of colorectal liver metastases: correlation with intra-operative sonography, surgical and pathological findings

AIM: To assess whether dual phase helical computed tomography (DPCT) of the liver improves the detection of colorectal liver metastases compared with portal venous phase (PVP) imaging alone. MATERIALS AND METHODS: DPCT was performed in 33 consecutive patients before laparotomy for resection of colorectal liver metastases. CT comprised 8-mm slice collimation with a pitch of 1 to 1.25; imaging was commenced 20-25 and 65-70 s after the start of injection of 150 ml of contrast medium at 5 ml/s to coincide with hepatic arterial phase (HAP) and PVP contrast enhancement, respectively. Four blinded observers independently reviewed the HAP, PVP and DPCT images recording the site and size of all lesions. Alternative-free response receiver operating characteristic (AFROC) methodology was used to analyse the results, which were correlated with surgery, intra-operative ultrasound and histology. RESULTS: The mean observer sensitivities for malignant lesion detection were 75.3% for DPCT, 69.7% for PVP imaging and 66.7% for HAP imaging alone. There was a statistically significant improvement in malignant lesion detection using DPCT when compared with PVP imaging alone (P < 0.05). The mean areas under the AFROC curves were 0.84 for DPCT and 0.82 for PVP (P < 0.03) imaging alone. CONCLUSION: The detection of colorectal liver metastases was marginally better with DPCT than with PVP imaging alone, but the discovery of additional lesions did not affect the management of any of the patients in this study.     

Role of PET/CT in the detection of liver metastases from colorectal cancer

Purpose

The aim of this study was to compare the diagnostic accuracy of 2-[fluorine-18] fluoro-2-deoxy-D-glucose positron emission tomography (¹⁸F-FDG-PET) and computed tomography (CT) with PET/CT in the detection of liver metastases during tumour staging in patients suffering from colorectal carcinoma for the purposes of correct surgical planning and follow-up.

Materials and methods

A total of 467 patients underwent a PET/CT scan using an iodinated contrast medium. We compared images obtained by the single PET scan, the single CT scan and by the fusion of the two procedures (PET/CT). The final diagnosis was obtained by histological examination and/or by the follow-up of all patients, including those who did not undergo surgery or biopsy.

Results

The PET scan had 94.05% sensitivity, 91.60% specificity and 93.36% accuracy; the CT scan had 91.07% sensitivity, 95.42% specificity and 92.29% accuracy. The combined procedures (PET/CT) had the following values: sensitivity 97.92%, specificity 97.71% and accuracy 97.86%.

Conclusions

This study indicates that PET/CT is very useful in staging and restaging patients suffering from colorectal cancer. It was particularly useful when recurrences could not be visualised either clinically or by imaging despite increasing tumour markers, as it guaranteed an earlier diagnosis. PET/CT not only provides high diagnostic performance in terms of sensitivity and specificity, enabling modification of patient treatment, but it is also a unique, high-profile procedure that can produce cost savings.     

原发性肝癌多层面CT双动脉期与门静脉期增强扫描分析

目的：探讨原发性肝癌多层面CT（multi-slices CT,MSCT）双动脉期与门静脉期增强扫描各期强化特征及癌灶的检出率。方法：104例原发性肝癌治疗前行MSCT的平扫与三期扫描（双动脉期与门静脉期扫描）,对比剂用量100 ml,以3 ml/s的速率肘静脉注射,采集时间动脉早期20～22 s,动脉晚期34～37 s,门静脉期60 s。测病灶平扫及各增强期CT值,分析病灶的强化情况及检出情况,以增强各期检出的肿瘤数目为肿瘤灶总数。结果：三期增强扫描共显示470个病灶,34个均匀强化;436个不均匀强化,〈3 cm病灶动脉早期检出117个（56.25%）,动脉晚期检出171个（82.21%）,门静脉期检出137个（65.86%）,≥3 cm的病灶动脉早期检出237个（90.45%）,动脉晚期检出250个（95.41%）,门静脉期检出244个（93.12%）。56个仅在三期增强扫描的一期显示,动脉早期5个,动脉晚期25个,门静脉期26个。结论：动脉晚期的检出率明显高于门静脉期与动脉早期。双动脉期与门静脉期增强扫描有利于提高肝癌检出效率。     

Quantification of hepatic arterial and portal venous flow using ultrasound contrast agents for early detection of liver metastases of colorectal cancers

PURPOSE: To quantify liver blood flow using US contrast agents and to evaluate arterial and portal changes in control patients and patients with liver metastases. MATERIALS AND METHODS: Twenty eight patients were included in this study, 8 controls (M0) and 20 patients with liver metastases from colon carcinoma (M+). Hepatic blood flow from hepatic artery and portal vein were determined using quantification of enhancement after contrast injection using Power Doppler US. The ratio of enhancement rise from artery and vein allows calculation of Contrast Enhanced Doppler Perfusion Index (CEDPI) as previously described for Doppler Perfusion Index (DPI). RESULTS: A significant difference was noted for CEDPI between controls (0.49 +/- 0.07) and liver with metastases (0.70 +/- 0.12). CONCLUSION: This functional method of evaluation of liver blood flow was easy to perform, and would be valuable for early detection of overt micro-metastases before anatomical changes observed by conventional imaging. This is helpful for accurate staging of colon carcinoma.     

Subtraction-multiphase-CT unbeneficial for early detection of colorectal liver metastases

Purpose

To assess the value of multiphase-subtraction-CT for early detection of colorectal-liver-metastases (CRLM).

Methods and materials

In 50 patients suspected of CRLM a routine pre-operative 4-phase-CT-scan of the upper abdomen was obtained. All 12 possible image subtractions between two different phases were constructed applying 3D-image-registration to decrease distortion artefacts induced by differences in inspiration volume. Two experienced radiologists initially reviewed the conventional 4-phase-CT for malignant and/or benign appearing lesions and at least 1-month hereafter the same 4-phase-CT now including the subtracted images. The results were compared to histology reports or to a combination of surgical exploration and intraoperative ultrasound together with results from pre-operative PET and follow-up examinations.

Results

Although an additional number of 31 malignant appearing lesions were detected on the subtraction images, none proved to represent a true CRLM. Interobserver agreement (κ) decreased from 0.627 (good) to 0.418 (fair).

Conclusion

Adding linearly co-registered subtraction-CT images to a conventional 4-phase-CT protocol does not improve detection of CRLM.     

Detection of liver metastases from colorectal cancer: comparison of intraoperative US and CT during arterial portography.

A prospective study was performed to compare the sensitivities of intraoperative ultrasound (US) and computed tomography during arterial portography (CTAP) in the depiction of hepatic metastases from colorectal cancer. Twenty-five patients with hepatic metastases from colorectal cancer were evaluated. All patients underwent partial hepatectomy, and 56 metastases were pathologically proved. Preoperatively, CTAP depicted 51 of the 56 metastases (91%). Intraoperative US depicted 54 of the 56 metastases (96%). Intraoperative US depicted three metastases (5%) that were not depicted with CTAP and two that were missed with palpation (3%). Furthermore, intraoperative US did not demonstrate any false-positive lesions. There was no statistically significant difference in sensitivity between the two techniques. The authors concluded that intraoperative US does not enable detection of more liver metastases from colorectal cancer when CTAP is considered as the preoperative standard of reference. Nevertheless, the results of the study suggest that intraoperative US and CTAP are complementary techniques, and the preoperative use of CTAP for determining the feasibility of hepatic resection cannot prevent the use of intraoperative US.     

Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT

PURPOSE: To prospectively evaluate helical computed tomography (CT) in the preoperative detection of hepatic metastases and assessment of resectability with surgical, intraoperative ultrasonographic (US), and histopathologic correlation. MATERIALS AND METHODS: Between October 1995 and December 1998, preoperative staging with helical CT (5-mm collimation; reconstruction interval, 5 mm) was performed in 157 patients with hepatic metastases. Iodinated contrast material was injected intravenously (160-170 mL; rate, 2.5-3.0 mL/sec); acquisition began at 60-70 seconds. Four radiologists prospectively assessed the metastatic involvement of the liver by indicating the number and location of the lesions; resection was indicated in 113 patients (119 instances). Helical CT findings were correlated with pathologic and surgical findings on a lesion-by-lesion basis. RESULTS: Intraoperative US, palpation, and histopathologic examination revealed 290 liver metastases; helical CT correctly depicted 247. Helical CT results were the following: overall detection rate, 85.1% (95% CI: 80.8%, 89.3%); positive predictive value, 96.1% (95% CI: 92.9%, 98.1%); and false-positive rate, 3.9% (10 of 257 findings; 95% CI: 1.9%, 7.1%). False-positive findings were related to hemangioendothelioma, hemangioma, hepatic peliosis, biliary adenoma, centrilobar hemorrhage, biliary hamartoma, periportal fibrosis, and normal liver parenchyma. Curative resection was performed in 112 instances with a resectability rate of 94.1%. Four-year patient survival rate was 58.6%. CONCLUSION: Helical CT is a noninvasive, reliable, and accurate technique for imaging the liver and should be considered as the standard preoperative work-up of hepatic metastases from colorectal cancer.     

Small colorectal liver metastases: Detection with SPIO-enhanced MRI in comparison with gadobenate dimeglumine-enhanced MRI and CT imaging

The aim of this prospective study was to compare the diagnostic role of superparamagnetic iron oxide (SPIO)-enhanced liver magnetic resonance imaging (MRI) versus gadobenate dimeglumine (GbD)-enhanced MRI and computed tomography (CT) investigations for detection of small (less than 1 cm) colorectal liver metastases (LMs) of colorectal cancer. Seventy-eight LMs in 16 patients were evaluated with dynamic CT imaging, GbD-enhanced dynamic MR imaging and SPIO-enhanced MR imaging. Two radiologists were reviewed the LMs seperately. Agreement between the readers and three algorithms was analyzed. Differences between the lesion detection ratios of the methods were analyzed by two proportion z test. Sensitivity values of each modality were also calculated. Interobserver agreement values with kappa analysis were found to be the best for three modalities and kappa values were 0.866, 0.843, and 1.0 respectively. For all 78 LMs, SPIO-enhanced MRI detected all lesions (100% sensitivity). This sensitivity value was higher than GbD-enhanced MRI, and there was a significant difference (p < 0.05). GbD-enhanced MRI depicted 71 lesions and this modality could not detected 7 lesions (91% sensitivity). This modality had moderate sensitivity, and this value is greater than CT imaging, so there was a significant difference also (p < 0.05). Dynamic triphasic CT imaging detected 64 (R1) and 65 (R2) LMs. This modality had the lowest sensitivity (R1: 0.82, R2: 0.83 respectively). Only SPIO-enhanced MRI was able to detect all LMs less than 1 cm. LMs were the best detected with SPIO-enhanced MRI. We recommend SPIO-enhanced MRI to be the primary alternative modality especially for diagnosis of small colorectal LMs.     

Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT

Objectives

We compared the diagnostic performance of gadoxetic acid-enhanced MRI and 16-slice multidetector CT (MDCT) with respect to their abilities to detect hepatic metastases and differentiate hepatic metastases from hepatic cysts and haemangiomas.

Methods

67 patients with 110 liver metastases (size 0.3–2.5 cm), 33 haemangiomas (size 0.5–1.5 cm) and 17 cysts (size 0.3–1.0 cm) underwent 4-phase MDCT and gadoxetic acid-enhanced MRI, including early dynamic phases, post-contrast T₂ weighted turbo spin echo sequences and 20 min hepatocyte-selective phases. Two observers independently analysed each image in random order. Sensitivity and diagnostic accuracy for lesion detection and differentiation for MDCT and gadoxetic acid-enhanced MRI were calculated using receiver operating characteristic analysis.

Results

For both observers, the Az values of gadoxetic acid-enhanced MRI (mean, 0.982 and 0.981) were significantly higher than the Az values of MDCT (mean, 0.839 and 0.892) (p<0.05) for the detection of metastases and for the differentiation of metastases from haemangiomas and cysts. Sensitivities of gadoxetic acid-enhanced MRI with regard to the detection and characterisation of liver metastases (mean, 96.9% and 96.0%) were significantly higher than those of MDCT (mean, 78.7% and 75.0%) (p<0.05).

Conclusion

Gadoxetic acid-enhanced MRI showed higher diagnostic accuracy and sensitivity than did MDCT for the detection of hepatic metastases and for the differentiation between hepatic metastases and hepatic haemangiomas or cysts.The early detection and precise characterisation of liver metastases are crucial factors in liver imaging because the success of surgery and ablation therapy depends on the knowledge of the precise number and locations of metastatic lesions [144]. Multidetector-row CT (MDCT) has been widely used as a primary imaging modality for evaluating liver metastases because of its wide availability. However, there has been some concern that MDCT images may not accurately characterise small hepatic nodules that are “too small to characterise”, and may not sufficiently differentiate small hepatic metastases from small hepatic cysts or haemangiomas, which are the most frequently encountered causes of focal liver lesions on CT [5-7]. Furthermore, MDCT is less able to detect liver metastases than MRI using liver-targeted agents, such as superparamagnetic iron oxide [8-13]. Thus, with the advent of new MR contrast agents for liver imaging, considerable attention has been focused on the ability of MR contrast agents to detect and characterise small focal liver lesions relative to the conventional imaging modality or previously existing MR contrast agents.Gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA, gadoxetic acid disodium, Primovist®; Bayer HealthCare, Berlin, Germany) is a recently introduced dual-acting MR contrast agent that combines the properties of an extracellular space contrast (ECS) agent and a liver-specific agent [14-19]. The combination of these properties enables the acquisition of the early vascular-interstitial phase, which provides haemodynamic information, and the hepatocyte phase, which detects liver malignancies. Thus, gadoxetic acid has a potency to fulfil the dual requirements for early detection and accurate characterisation of focal liver lesions. To the best our knowledge, no previous study has evaluated the diagnostic capability of gadoxetic acid-enhanced MRI to detect and characterise liver metastases compared with MDCT. In this study, we retrospectively compared the diagnostic performance of gadoxetic acid-enhanced MRI and 16-slice MDCT in detecting small hepatic metastases and in differentiating hepatic metastases from hepatic haemangiomas and cysts, using alternative free-response receiver operating characteristic (ROC) analysis.     

Size of colorectal liver metastases at abdominal CT: comparison of precontrast and postcontrast studies

PURPOSE: To investigate whether measurements of hepatic metastases from colorectal carcinoma before contrast material administration are significantly different statistically from measurements after contrast material administration. MATERIALS AND METHODS: Twenty-four patients with hepatic metastases from colorectal carcinoma underwent spiral computed tomography (CT) with 7-mm collimation. The liver was imaged before and in the portal-dominant phase after intravenous contrast material administration. For each scan, one to three discrete liver lesions were selected for measurement (n = 49). Three experienced radiologists performed independent measurements of the selected lesions on both pre- and postcontrast images at a computer workstation. A three-way analysis of variance (ANOVA) was performed: subjects by raters (the three independent radiologists) by pre- or postcontrast status. The dependent variable was the product of bidimensional measurements. RESULTS: Sixty-seven percent (33 of 49) of the lesions were measured as larger on precontrast images; 33% (16 of 49), as smaller. There was high interrater reliability, with an intraclass correlation coefficient greater than 0.9 ANOVA showed significant subject, rater, and contrast material effects (P < .001) for the largest lesions in each liver. Contrast material status was a significant factor for all lesion sizes (P < .003). CONCLUSION: On average, hepatic metastases from colorectal carcinoma are significantly smaller after contrast material administration.     

Revealing hepatic metastases from colorectal cancer: value of combined helical CT during arterial portography and CT hepatic arteriography with a unified CT and angiography system

OBJECTIVE: The purpose of our study was to evaluate the use of combined helical CT during arterial portography and CT hepatic arteriography in the preoperative assessment of hepatic metastases from colorectal cancer using a unified CT and angiography system. MATERIALS AND METHODS: Fifty-four patients with hepatic metastases from colorectal cancer preoperatively underwent combined CT during arterial portography and CT hepatic arteriography using the unified CT and angiography system. Three radiologists independently and retrospectively reviewed the images of CT during arterial portography alone, CT hepatic arteriography alone, and combined CT during arterial portography and CT hepatic arteriography. Image review was conducted on a segment-by-segment basis; a total of 432 hepatic segments with (n = 103) 118 metastatic tumors ranging in size from 2 to 160 mm (mean, 25.8 mm) and without (n = 329) tumor were reviewed. RESULTS: Relative sensitivity of combined CT during arterial portography and CT hepatic arteriography (87%) was higher than that of CT during arterial portography alone (80%, p < 0.0005) and CT hepatic arteriography alone (83%, p < 0.005). Relative specificity of CT hepatic arteriography alone (95%, p < 0.0005) and combined CT during arterial portography and CT hepatic arteriography (96%, p < 0.0001) was higher than that of CT during arterial portography alone (91%). Diagnostic accuracy, determined by a receiver operating characteristic curve analysis, was greater with combined CT during arterial portography and CT hepatic arteriography than with CT during arterial portography alone (p < 0.05) or CT hepatic arteriography alone (p < 0.01). CONCLUSION: Using a unified CT and angiography system, we found that combined CT during arterial portography and CT hepatic arteriography significantly raised the detectability of hepatic metastases from colorectal cancer.     

Comparison of unenhanced, hepatic arterial-dominant, and portal venous-dominant phase helical CT for the detection of liver metastases in women with breast carcinoma

OBJECTIVE: The purpose of this study was to evaluate triple-phase helical CT for detection of hepatic metastases from breast carcinoma. SUBJECTS AND METHODS: Breast cancer patients were studied prospectively with triple-phase helical CT in 300 consecutive examinations. Hepatic arterial-dominant and portal venous-dominant phase scans were initiated at 20 and 65 sec, respectively, after IV injection of 175 ml of iopamidol (30 mg/ml) at 5 ml/sec. Three independent observers each reviewed 200 cases of the portal venous-dominant phase for lesion number, conspicuity, and attenuation. Subsequently, portal venous-dominant phase images were reevaluated in conjunction with hepatic arterial-dominant phase or unenhanced images. RESULTS: Hepatic metastases were identified in 79 (26%) of 300 cases. Lesions detected on portal venous-dominant, hepatic arterial-dominant, and unenhanced images were as follows: observer 1, n = 198, 164, and 171; observer 2, n = 254, 233, and 233; and observer 3, n = 291, 270, and 276 (p > .05). The mean total lesion count was 387, with more lesions detected on portal venous-dominant phase than on either hepatic arterial-dominant phase or unenhanced images (p < .001 and p < .0001, respectively). For individual observers, 10-26% of lesions were hypervascular on hepatic arterial-dominant phase images. Two to 4% of lesions were identified only on hepatic arterial-dominant phase or unenhanced images. However, in these few cases, the lesions either were false-positives or were seen in conjunction with additional metastases on portal venous-dominant images. CONCLUSION: Routine use of triple-phase CT in patients with breast carcinoma may not be warranted: Addition of the hepatic arterial-dominant phase or unenhanced images revealed few additional lesions in our group of 300 patients.     

Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases

ObjectivesSurgical resection and radio-frequency ablation (RFA) are standard therapeutic procedures for colorectal metastases confined to the liver. The presence of extrahepatic disease has a significant effect on the management of these patients. The goal of this study is to assess the value of positron emission tomography/computed tomography with 18F-fluorodeoxyglucose (18F-FDG PET/CT) in the decision making whether to perform RFA or surgical resection of liver metastases in patients with metastatic colorectal cancer.Material and methodsThirty-five consecutive patients (23 men, 12 women; age range: 46–78 years) with colorectal carcinoma and liver metastases were prospectively enrolled. Nineteen of them were considered candidates for surgical resection and 16 for RFA. All underwent 18F-FDG PET/CT, helical computed tomography of the chest and abdomen and, some of them, magnetic resonance imaging of the abdomen. The 18F-FDG PET/CT studies were performed within 4 weeks from conventional imaging, and additional findings were later confirmed or not, either by histology or follow up.ResultsIn the surgical candidate group, 18F-FDG PET/CT detected extrahepatic disease, missed by conventional imaging, in 9/19 patients (47.3%). These findings directly altered the management in 7 patients (36.8%). In the group of RFA candidates, 18F-FDG PET/CT detected additional extrahepatic disease in 4/16 patients (25%) and directly altered management in all of them. Overall, in 11/35 patients (31.4%), 18F-FDG PET/CT detected extrahepatic metastatic disease.ConclusionIn patients with colorectal cancer and liver metastases, 18F-FDG PET/CT provides relevant additional information that has significant impact on management.     

Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases

Objectives

To compare the diagnostic accuracy of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MRI, diffusion-weighted MRI (DW-MRI) and a combination of both techniques for the detection of colorectal hepatic metastases.

Methods

72 patients with suspected colorectal liver metastases underwent Gd-EOB-DTPA MRI and DW-MRI. Images were retrospectively reviewed with unenhanced T₁ and T₂ weighted images as Gd-EOB-DTPA image set, DW-MRI image set and combined image set by two independent radiologists. Each lesion detected was scored for size, location and likelihood of metastasis, and compared with surgery and follow-up imaging. Diagnostic accuracy was compared using receiver operating characteristics and interobserver agreement by kappa statistics.

Results

417 lesions (310 metastases, 107 benign) were found in 72 patients. For both readers, diagnostic accuracy using the combined image set was higher [area under the curve (Az) = 0.96, 0.97] than Gd-EOB-DTPA image set (Az = 0.86, 0.89) or DW-MRI image set (Az = 0.93, 0.92). Using combined image set improved identification of liver metastases compared with Gd-EOB-DTPA image set (p<0.001) or DW-MRI image set (p<0.001). There was very good interobserver agreement for lesion classification (κ = 0.81–0.88).

Conclusions

Combining DW-MRI with Gd-EOB-DTPA-enhanced T₁ weighted MRI significantly improved the detection of colorectal liver metastases.In patients with colorectal cancer, accurate assessment of the size, location and segmental distribution of liver metastases on a per-lesion basis is critical for treatment planning [1]. Accurate depiction of the size and distribution of liver metastases helps the selection of patients to undergo radical surgery [2,3] or minimally invasive therapy, such as radiofrequency ablation (RFA) [4], chemo-embolisation or radio-embolisation [5].The image contrast in diffusion-weighted MRI (DW-MRI) is based on differences in the mobility of water between tissues [6]. In tumour tissues, such as liver metastases, water mobility is often more impeded compared with normal parenchyma. Hence, metastases appear to have high signal intensity on DW-MRI, facilitating their detection.Compared with conventional T₂ weighted imaging, DW-MRI has been found to be superior for lesion detection in the liver [7-9]. When compared with contrast-enhanced MRI, DW-MRI had a higher diagnostic accuracy compared with superparamagnetic iron oxide (SPIO)-enhanced MRI [10] and similar diagnostic accuracy compared with gadolinium contrast-enhanced imaging [11] for detecting colorectal liver metastases. DW-MRI has also been found to be more sensitive than fluorodeoxyglucose (¹⁸FDG) positron emission tomography (PET) CT [12] for the same clinical indication. In another study, combining DW-MRI with T₁ weighted imaging after liver-specific contrast medium mangafodipir trisodium (MnDPDP) administration improved the diagnostic accuracy of colorectal liver metastases detection compared with either technique alone [13].Gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid (Gd-EOB-DTPA; Eovist or Primovist; Bayer Schering Pharma, Berlin, Germany) is a relatively new hepatocyte-selective MR contrast medium that has been shown to be useful detecting liver metastases measuring <1 cm in diameter [14,15]. Delayed T₁ weighted imaging in the hepatocellular phase of contrast enhancement at 20 min to several hours after contrast administration demonstrates metastases as T₁ hypointense lesions against the avidly enhancing liver parenchyma.Both DW-MRI and Gd-EOB-DTPA-enhanced MRI are useful for the detection of liver metastases [7,8,14-16]. One study performed at 3 T compared the diagnostic performance of the two techniques for the identification of small (<2 cm) liver metastases [17]. Another study at 1.5 T independently compared the diagnostic performance of DW-MRI, dynamic phase MRI and hepatobiliary phase Gd-EOB-DTPA-enhanced MRI [18]. However, the possible incremental value of combining DW-MRI with Gd-EOB-DTPA-enhanced MRI for detecting colorectal metastases has not been reported. Hence, the aim of this study was to compare the diagnostic accuracy of Gd-EOB-DTPA-enhanced MRI, DW-MRI and a combination of both techniques for the detection of colorectal hepatic metastases.     

Liver metastases from colorectal carcinoma: detection with continuous CT angiography.

A diagnostic approach to assess liver metastases from colorectal carcinoma was prospectively evaluated in 30 patients with and without metastases on the basis of findings at conventional computed tomography (CT). With the technique, termed continuous CT angiography (CCTA), CT data were continuously sampled for 24 seconds at the same section level after initiation of a 3-second injection of 10-20 mL of contrast medium in the common hepatic artery. The procedure was repeated for each contiguous section level of the liver. Findings at preoperative ultrasound (US), conventional CT, and CCTA were compared with those at intraoperative US and surgical exploration as the standard of reference. Forty-four liver metastases were identified in 16 patients, and 14 patients had no metastases. CCTA had a sensitivity of 98% (43 lesions identified) and higher accuracy (81% [54 of 67 diagnoses]) than US and conventional CT. The data indicate that CCTA can supplement information obtained with conventional imaging techniques in patients who must undergo hepatic surgery because of metastases from colorectal carcinoma.     

Liver metastases from colorectal cancers: detection with CT during arterial portography

A total of 45 metastases to the liver from colorectal cancer were resected in 22 patients. The detectability of these lesions with the following modalities was determined: real-time ultrasound (US), computed tomography (CT), selective celiac arteriography (SCA), infusion hepatic angiography (IHA), CT during arterial portography (CTAP), and CT following intraarterial injection of iodized poppyseed oil (Lipiodol). The total detection rate (sensitivity) was 58% for US, 63% for CT, 27% for SCA, 50% for IHA, 84% for CTAP, and 38% for CT with iodized oil. Ten of 18 lesions less than 15 mm in largest diameter were demonstrated preoperatively by CTAP only. CTAP is useful in clarifying the locations of the lesions in the liver and should always be performed before liver metastases from colorectal cancer are resected.     

结直肠癌肝转移MRI:口服锰与静脉注射钆贝酸二葡甲胺比较

目的比较口服锰对比剂(CMC-001)与常规剂量静脉注射钆贝酸二葡甲胺后,MRI检测结直肠癌肝转移(CRLM)的敏感性,评估口服锰的安全性和可接受性。方法选取20例怀疑有1～6个CRLM灶的病人进行前瞻性的随机